SELLAS Life Sciences Group, Inc. (FRA:RXK3)
1.286
+0.058 (4.72%)
At close: Nov 28, 2025
FRA:RXK3 Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 44.32 | 13.89 | 2.53 | 17.13 | 21.36 | 35.3 | Upgrade |
Cash & Short-Term Investments | 44.32 | 13.89 | 2.53 | 17.13 | 21.36 | 35.3 | Upgrade |
Cash Growth | 110.74% | 448.85% | -85.23% | -19.81% | -39.51% | 385.12% | Upgrade |
Prepaid Expenses | 0.45 | 0.17 | 0.14 | 0.3 | 0.25 | 0.27 | Upgrade |
Restricted Cash | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | Upgrade |
Other Current Assets | 4.18 | 2.17 | 0.4 | 0.23 | 1.34 | 1.25 | Upgrade |
Total Current Assets | 49.05 | 16.33 | 3.17 | 17.76 | 23.04 | 36.93 | Upgrade |
Property, Plant & Equipment | 0.56 | 0.93 | 0.86 | 0.87 | 0.72 | 0.9 | Upgrade |
Goodwill | 1.91 | 1.91 | 1.91 | 1.91 | 1.91 | 1.91 | Upgrade |
Other Intangible Assets | - | - | - | - | - | 5.7 | Upgrade |
Other Long-Term Assets | 0.03 | 0.27 | 0.28 | 0.4 | 0.59 | 0.61 | Upgrade |
Total Assets | 51.56 | 19.43 | 6.22 | 20.94 | 26.28 | 46.05 | Upgrade |
Accounts Payable | 2.31 | 3.5 | 5.64 | 3.36 | 2.14 | 4.66 | Upgrade |
Accrued Expenses | 2.99 | 5.42 | 7.61 | 6.29 | 2.48 | 1.72 | Upgrade |
Current Portion of Leases | 0.6 | 0.54 | 0.45 | 0.37 | 0.2 | 0.17 | Upgrade |
Current Unearned Revenue | - | - | - | - | - | 5.6 | Upgrade |
Other Current Liabilities | 0.03 | 0.04 | 0.04 | 5.5 | 0.16 | 0.19 | Upgrade |
Total Current Liabilities | 5.93 | 9.51 | 13.74 | 15.52 | 4.98 | 12.34 | Upgrade |
Long-Term Leases | - | 0.46 | 0.46 | 0.57 | 0.61 | 0.83 | Upgrade |
Long-Term Deferred Tax Liabilities | - | - | - | - | - | 0.24 | Upgrade |
Other Long-Term Liabilities | - | - | - | 0 | 0.34 | 4.69 | Upgrade |
Total Liabilities | 5.93 | 9.97 | 14.2 | 16.09 | 5.93 | 18.09 | Upgrade |
Common Stock | 0.01 | 0.01 | 0 | 0 | 0 | 0 | Upgrade |
Additional Paid-In Capital | 312.95 | 257.58 | 209.27 | 184.75 | 158.95 | 145.86 | Upgrade |
Retained Earnings | -267.33 | -248.13 | -217.24 | -179.9 | -138.6 | -117.9 | Upgrade |
Shareholders' Equity | 45.63 | 9.47 | -7.98 | 4.85 | 20.35 | 27.96 | Upgrade |
Total Liabilities & Equity | 51.56 | 19.43 | 6.22 | 20.94 | 26.28 | 46.05 | Upgrade |
Total Debt | 0.6 | 1 | 0.91 | 0.95 | 0.81 | 0.99 | Upgrade |
Net Cash (Debt) | 43.72 | 12.89 | 1.62 | 16.18 | 20.55 | 34.31 | Upgrade |
Net Cash Growth | 113.74% | 693.41% | -89.96% | -21.25% | -40.12% | 385.99% | Upgrade |
Net Cash Per Share | 0.47 | 0.21 | 0.06 | 0.83 | 1.33 | 4.30 | Upgrade |
Filing Date Shares Outstanding | 142.44 | 90.85 | 56.27 | 28.3 | 15.91 | 15.08 | Upgrade |
Total Common Shares Outstanding | 125.08 | 73.98 | 32.13 | 21.01 | 15.9 | 14.25 | Upgrade |
Working Capital | 43.13 | 6.82 | -10.56 | 2.24 | 18.06 | 24.59 | Upgrade |
Book Value Per Share | 0.36 | 0.13 | -0.25 | 0.23 | 1.28 | 1.96 | Upgrade |
Tangible Book Value | 43.72 | 7.55 | -9.89 | 2.94 | 18.43 | 20.35 | Upgrade |
Tangible Book Value Per Share | 0.35 | 0.10 | -0.31 | 0.14 | 1.16 | 1.43 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.